Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3234 Dissociated response as a new biomarker of treatment response in neuroendocrine tumors: Results from phase 3 of the RAISE project

Introduction: RAISE aimed to find a surrogate endpoint to early predict treatment efficacy in patients with neuroendocrine tumors (NET). Dissociated response is the inhomogeneous response of the different lesions of a patient. Its prognostic value remains unclear.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Dromain C

Authors: Dromain C, Pavel M, Ronot M, Schaefer N, Mandair D,

Keywords: neuroendocrine tumor, dissociated response, progression-free survival, prediction,

#3229 The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors: Results from phase 3 of the RAISE project

Introduction: Response Evaluation Criteria in Solid Tumors (RECIST) assesses treatment response via tumor progression in patients with neuroendocrine tumors (NET). RAISE combined deep learning models (DLM) with sum of the longest diameter (SLD) of liver lesions and chromogranin A (CgA) to find a surrogate endpoint for RECIST to early predict progression-free survival (PFS).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Pavel M

Authors: Pavel M, Dromain C, Ronot M, Schaefer N, Mandair D,

Keywords: neuroendocrine tumor, deep learning models, progression-free survival, prediction,

#2261 Mechanisms of Main Pancreatic Duct Dilatation in Pancreatic Neuroendocrine Tumors (PanNETs): Radiopathologic Correlation

Introduction: Main pancreatic duct (MPD) dilatation, a frequent observation in cases with adenocarcinoma can also be observed in patients with PanNET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ronot M

Authors: Ronot M, Cros J, Faccinetto A, de Mestier L, Hentic O,

Keywords: Sclerozing PanNET, MRI, Main duct dilatation,

#2102 Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study

Introduction: TGR0 >4%/month was associated with shorter progression-free survival (PFS) in patients (pts) treated with lanreotide in the CLARINET study. Impact of TGR0 in pts treated with other systemic therapies (ST) and with Ki67>10% is unknown.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Crona J

Authors: Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C,

Keywords: tumor growth rate, TGR, RECIST, Neuroendocrine Tumor,

#2053 Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients’ Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study

Introduction: TGR (% change in tumour volume per month (%/m)) is postulated to be an early radiological biomarker to overcome limitations of RECIST in NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lamarca A

Authors: Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C,

Keywords: tumor growth rate, response, progression-free survival, follow-up, neuroendocrine tumor, prognosis, TGR, RECIST, radiology,